Статья
РЕНАЛЬНАЯ ДЕНЕРВАЦИЯ: ОБЗОР
Представлен обзор литературы, описывающий современное состояние вопроса и перспективы развития малоинвазивного направления в лечении резистентной к терапии артериальной гипертензии – ренальной денервации.
1. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014; 23: 3–16.
2. Pimenta E., Calhoun D. A. Resistant hypertension: incidence, prevalence and prognosis. Circulation. 2012; 125: 1594–1596.
3. Calhoun D. A., Jones D., Textor S., Goff D. C., Murphy T. P., Toto R. D. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51: 1403–1419.
4. Wright J. T., Williamson J. D., Whelton P. K., Snyder J. K., Sink K. M., Rocco M. V. et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England Journal of Medicine. 2015; 373 (22): 2103–2116.
5. Daugherty S. L., Powers J. D., Magid D. J. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125 (13): 1635–1642.
6. Grimson K. S., Orgain E. S., Anderson B., Broome R. A., Longino F. H. Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy. Ann. Surg. 1949; 129: 850–871.
7. Smithwick R. H., Thompson J. E. Splanchnicectomy foressential hypertension:results in 1,266 cases. J. Am. Med. Assoc. 1953; 152: 1501–1504.
8. Krum H., Schlaich M., Whitbourn R., Sobotka P. A., Sadowski J., Bartus K. et al. Catheter- based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373 (9671): 1275–1281.
9. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376: 1903–1909.
10. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011; 57: 911–917.
11. Persu А., Renkin J., Thijs L., Staessen J. A. Renal Denervation Ultima Ratio or Standard in Treatment-Resistant Hypertension. Hypertension. 2012; 60: 596–606.
12. Bhatt D. L., Kandzari D. E., O’Neill W. W., D’Agostino R., Flack J. M., Katzen B. T. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014; 370: 1393–1401.
13. Brinkmann J., Heusser K., Schmidt B. M., Menne J., Klein G., Bauersachs J. et al. Catheter- based renal nerve ablation and centrally generated sympathetic activity in difficultto- control hypertensive patients: prospective case series. Hypertension. 2012; 60: 1485–1490.
14. Kandzari D. E., Bhatt D. L., Brar S., Devireddy C. M., Esler M., Fahy M. et al. Predictors of blood pressure response in the SYMPLICITY HTN-3trial. European Heart Journal. 2015; 36: 219–227.
15. Thomas F., Scher L., Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? European Heart Journal. 2014; (35): 1706–1711.
16. Böhm M., Mahfoud F., Ukena C. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015; 65 (4): 766–774.
17. Azizi M., Sapoval M., Gosse P., Monge M., Bobrie G., Delsart P. et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, openlabel, randomised controlled trial. Lancet. 2015; 385 (9981): 1957–1965.
18. De Jager R. L., Sanders M. F., Bots M. L. Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clin. Res. Cardiol. 2016; 105 (9): 755–762.
19. Rosa J., Widimský P., Toušek P., Petrák O., Čurila K., Waldauf P. et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: Six-month results from the prague-15 study. Hypertension. 2015; 65 (2): 407–413.
20. Oliveras A., Armario P., Clarà A. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: Results from the DENERVHTA study - A randomized controlled trial. Journal of Hypertension. 2016; 34 (9): 1863– 1871.
21. DiBona G. F. The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004; 43: 147–150.
22. Booth L. C., Nishi E. E., Yao S. T., Ramchandra R., Lambert G. W., Schlaich M. P. et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheterbased radio-frequency renal denervation in sheep. Hypertension. 2015; 65: 393– 400.
23. de Jong M. R., Adiyaman A., Gal P., Smit J. J., Delnoy P. P., Heeg J. E. et al. Renal Nerve Stimulation-Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation. Hypertension. 2016; 68 (3): 707–714.
24. Hering D., Lambert E. A., Marusic P., Walton A., Krum H., Lambert G. W. et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013; 61: 457–464.
25. Esler M., Jennings G., Korner B., Blombery P., Sacharias N., Leonard P. Measurement of total and organ-specific nor-epinephrine kinetics in humans. Am. J. Physiol. 1984; 247: 21– 28.
26. Kingwell B. A., Thompson J. M., Kaye D. M., McPherson G. A., Jennings G. L., Esler M. D. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathtic nerve activity during human sympathetic nervous activation and failure. Circulation. 1994; 90: 234–240.
27. Henegar J. R., Zhang Y., De Rama R., Hata C., Hall M. E., Hall J. E. Catheter-based radiorefrequency renal denervation lowers blood pressure in obese hypertensive dogs. Am. J. Hypertens. 2014; 27: 1285–1292.
28. Krum H., Schlaich M. P., Sobotka P. A., Böhm M., Mahfoud F., Rocha-Singh K. et al. Percutaneous renal denervation in patients with treatment resistant hypertension: final 3- year report of the Symplicity HTN-1 study. Lancet. 2014; 383 (9917): 622–629.
29. Booth L. C., Nishi E. E., Yao S. T., Ramchandra R., Lambert G. W., Schlaich M. P. et al. Reinnervation following catheter-based radio-frequency renal denervation. Exp. Physiol. 2015; 100 (5): 485–490.
30. Kline R. L., Mercer P. F. Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1980; 238: 353–358.
31. Mulder J., Hokfelt T., Knuepfer M. M., Kopp U. C. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013; 304: 675–682.
32. Hansen J. M., Abildgaard U., Fogh-Andersen N., Kanstrup I. L., Bratholm P., Plum I. et al. The transplanted human kidney does not achieve functional reinnervation. Clin. Sci. (Lond). 1994; 87: 13–20.
33. Sakakura K., Ladich E., Cheng Q., Otsuka F., Yahagi K., Fowler D. R. et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J. Am. Coll. Cardiol. 2014; 64: 635–643.
34. Mahfoud F., Tunev S., Ewen S., Cremers B., Ruwart J., Schulz-Jander D. et al. Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. J. Am. Coll. Cardiol. 2015; 20; 66 (16): 1766–1775.
35. Баев А. Е., Пекарский С. Е., Мордовин В. Ф., Крылов А. Л., Ситкова Е. С. Ренальная денервация. Оптимизация техники. Эффективность и безопасность. Международный журнал интервенционной кардиоангиологии. 2013; 35: 24. Baev A. E., Pekarskij S. E., Mordovin V. F., Krylov A. L., Sitkova E. S. Renal’naja denervacija. Optimizacija tehniki. Jeffektivnost’ i bezopasnost’. Mezhdunarodnyj zhurnal intervencionnoj kardioangiologii. 2013; 35: 24.
36. Chen W., Ling Z., Du H., Song W., Xu Y., Liu Z. et al. The effect of two different renal denervation strategies on blood pressure in resistant hypertension: Comparison of fulllength versus proximal renal artery ablation. Catheter Cardiovasc Interv. 2016. DOI: 10.1002/ccd.26594.
37. de Jong M. R., Hoogerwaard A. F., Gal P. Adiyaman A., Smit J. J., Delnoy P. P. et al. Persistent Increase in Blood Pressure After Renal Nerve Stimulation in Accessory Renal Arteries After Sympathetic Renal Denervation. Hypertension. 2016; 67 (6): 1211–1217.
38. Vаclavik J., Taborsky M., Richter D. Unilateral catheter-based renal sympathetic denervation in resistant arterial hypertension shows no blood pressure-lowering effect. Clin. Exp. Hypertens. 2013; 35: 192–194.
39. Hutchinson B. D., Keane D., Dodd J. D. Renal sympathetic denervation: MDCT evaluation of the renal arteries. Am. J. Roentgenol. 2013; 201 (2): 342–346. DOI: 10.2214/AJR.12.8560.
40. Pua U., Tang A. A., Ooi Y. W., Ho H. H., Ong P. J. Safety and Feasibility of Renal Sympathetic Denervation in Patients With Insufficient Renal Artery Length. Vasc. Endovascular Surg. 2016; 50 (1): 63–67. DOI: 10.1177/1538574416629564.
41. Rippy M. K., Zarins D., Barman N. C., Wu A., Duncan K. L., Zarins C. K. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin. Res. Cardiol. 2011; 100: 1095–1101.
42. Versaci F., Trivisonno A., Olivieri C., Magri G., Caranci F., Prati F. Is an Abnormal Vascular Response After Renal Sympathetic Denervation Predictive of Permanent Damage?: An Unusual Case of Late Renal Artery Stenosis After Energy Delivery. J. Endovasc. Ther. 2014; 21: 191–196.
43. Sievert H., Schofer J., Ormiston J., Hoppe U. C., Meredith I. T., Walters D. L. et al. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE- HTN clinical study. EuroIntervention. 2015; 10 (10):1213–1220. DOI: 10.4244/EIJY14M12_01.
44. Fischell T. A., Ebner A., Gallo S., Ikeno F., Minarsch L., Vega F. et al. Transcatheter Alcohol- Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience. JACC Cardiovasc. Interv. 2016; 9 (6): 589–598. DOI: 10.1016/j. 2015.11.041.jcin.
45. Karanasos A. L., Van Mieghem N. L., Bergmann M. W., Hartman E., Ligthart J., van der Heide E. et al. Multimodality Intra-Arterial Imaging Assessment of the Vascular Trauma Induced by Balloon-Based and Nonballoon-Based Renal Denervation Systems. Circ. Cardiovasc. Interv. 2015; 8 (7): 002474. DOI: 10.1161/CIRCINTERVENTIONS.115.002474.
46. Brandt M. C., Mahfoud F., Reda S., Schirmer S. H., Erdmann E., Böhm M. et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 2012; 59: 901–909. DOI: 10.1016/j.jacc.2011.11.034.
47. Mortensen K., Franzen K., Himmel F., Bode F., Schunkert H., Weil J. et al. Catheter-based renal sympathetic denervation improves central hemodynamics and arterial stiffness: a pilot study. J. Clin. Hypertens. (Greenwich). 2012; 14: 861–870. DOI: 10.1111/j.1751176.2012.00704.
48. Doumas M., Anyfanti P., Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J. Hypertens. 2012; 30 (5): 874–876.
49. Мордовин В. Ф., Пекарский С. Е., Семке Г. В., Рипп Т. М., Фальковская А. Ю., Ситкова Е. С. и др. Использование современных медицинских технологий для диагностики и лечения больных артериальной гипертонией. Сибирский медицинский журнал (Томск). 2015; 30 (2): 29–35. Mordovin V. F., Pekarskij S. E., Semke G. V., Ripp T. M., Fal’kovskaja A. Ju., Sitkova E. S. i dr. Ispol’zovanie sovremennyh medicinskih tehnologij dlja diagnostiki i lechenija bol’nyh arterial’noj gipertoniej. Sibirskij medicinskij zhurnal (Tomsk). 2015; 30 (2): 29–35.
50. Huggett R. J., Scott E. M., Gilbey S. G., Stoker J. B., Mackintosh A. F., Mary D. A. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003; 108 (25): 3097–3101.
51. Mahfoud F., Schlaich M., Kindermann I., Ukena C., Cremers B., Brandt M. C. et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension. Pilot Study. Circulation. 2011; 123 (18): 1940– 1946.
52. Фальковская А. Ю., Мордовин В. Ф., Пекарский С. Е., Баев А. Е., Семке Г. В., Рипп Т. М. Дополнительные благоприятные эффекты симпатической денервации почек при лечении резистентной артериальной гипертензии у больных сахарным диабетом 2-го типа. Артериальная гипертензия. 2014; 20 (2): 107–112. Fal’kovskaja A. Ju., Mordovin V. F., Pekarskij S. E., Baev A. E., Semke G. V., Ripp T. M. Dopolnitel’nye blagoprijatnye jeffekty simpaticheskoj denervacii pochek pri lechenii rezistentnoj arterial’noj gipertenzii u bol’nyh saharnym diabetom 2-go tipaju. Arterial’naja gipertenzija. 2014; 20 (2): 107–112.
53. Schauerte P., Scherlag B. J., Patterson E., Scherlag M. A., Matsudaria K., Nakagawa H. et al. Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system. J. Cardiovasc. Electrophysiol. 2001; 12: 592–599.
54. Giannopoulos G., Kossyvakis K., Efremidis M. Central Sympathetic Inhibition to Reduce Postablation Atrial Fibrillation Recurrences in Hypertensive Patients A Randomized, Controlled Study. Circulation. 2014; 130 (16): 1346–1352. DOI: 10.1161/CIRCULATIONAHA.114.010999.
55. Pokushalov E., Romanov A., Corbucci G., Artyomenko S., Baranova V., Turov A. et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J. Am. Coll. Cardiol. 2012; 60: 1163–1170.
56. Qiu M., Shan Q., Chen C., Geng J., Guo J., Zhou X. et al. Renal sympathetic denervation improves rate control in patients with symptomatic persistent atrial fibrillation and hypertension. Acta Cardiol. 2016; 71 (1): 67–73. DOI: 10.2143/AC.71.1.3132100.
57. Parati G., Lombardi C., Hedner J., Bonsignore M. R. Position paper on the management of patients with obstructive sleep apnea and hypertention: joint recomendationby European Society of Hypertension, by the European Respiratory Society and by the members of European COST ACTION B26 on obstructive sleep apnea. J. Hypertens. 2012; 30: 633–646.
58. Mahfoud F., Linz D., Mancia G., Narkiewicz K., Ruilope L. M., Schlaich M. P. et al. Renal artery denervation for treatment of hypertensive patients with or without obstructive sleep apnea and resistant hypertension: Results from Global Symplisity Registry. J. Hypertens. 2015. DOI: 10.1097/01.hjh.0000467640.39623.b2.
59. Converse R. L., Jacobsen T. N., Toto R. D., Jost C. M., Cosentino F., Fouad-Tarazi F. et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 1992; 327: 1912–1918.
60. De Beus E., De Jager R., Joles J. A., Grassi G., Blankestijn P. J. Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation? J. Hypertens. 2014; 32 (9): 1751–1761. DOI: 10.1097/HJH.0000000000000210.
61. Hering D., Mahfoud F., Walton A. S., Krum H., Lambert G. W., Lambert E. A. et al. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 2012; 23: 1250–1257. DOI: 10.1681/ASN.2011111062.
62. Hering D., Walton A., Krum H. et al. Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. Int. J. Cardiol. 2012; 159: 35–36.
63. Mahfoud F., Tunev S., Ruwart J., Schulz-Jander D., Cremers B., Linz D. et al. Efficacy and safety of catheter-based radiofrequency renal denervation in stented renal arteries. Circ. Cardiovasc. Interv. 2014; 7 (6): 813–820.